Ph2 trials are typically done to assess efficacy AND safety. Usually in that order.
Ph1 defines safety, typically in a small cohort.
Ph2 explores efficacy and safety in a larger group.
Ph3 studies efficacy in a larger group again.
Ph4 is typically done post-marketing.
I am expecting the primary outcome to be met, and anything over and above 15% decrease in proteinuria to meet clinicalsignificance. That would warrant a Ph3.
Depends upon how the company releases it. If all patients show a 20% decrease? Or half of them show a 40% decrease and the remainder show a 10% decrease? Stats was never my strong suit.
And a Ph3 company in a FDA-designated orphan disease.... you can figure out the rest...
- Forums
- ASX - By Stock
- DXB
- Ann: Quarterly Appendix 4C and Activities Report
Ann: Quarterly Appendix 4C and Activities Report, page-209
-
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
|
|||||
Last
44.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $242.0M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 2621 | 45.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
44.0¢ | 418 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 2624 | 0.455 |
2 | 1211 | 0.450 |
2 | 33249 | 0.445 |
1 | 70000 | 0.440 |
2 | 10900 | 0.435 |
Price($) | Vol. | No. |
---|---|---|
0.440 | 418 | 1 |
0.445 | 25792 | 3 |
0.450 | 11613 | 2 |
0.455 | 15230 | 2 |
0.460 | 134949 | 3 |
Last trade - 09.57am 10/07/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |
Day chart unavailable
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online